Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of Wall Street expectations, and maintained guidance for 2025 it had laid out in December.
Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance
Pfizer Inc. shares rose 1.7% in premarket trades Tuesday after the drug maker topped Wall Street’s revenue and profit estimates in its fourth-quarter results and reaffirmed its full-year guidance. Pfizer’s adjusted fourth-quarter profit of 63 cents a share beat the FactSet consensus estimate of 47 cents a share.
Pfizer Beats Q4 Revenue, EPS Estimates
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.
Pfizer Maintains Full-Year Outlook Following Fourth-Quarter Beat
Pfizer's (PFE) fourth-quarter results topped market expectations amid double-digit revenue growth across key segments, while the pharmaceutical giant reiterated its full-year outlook. The company on Tuesday posted adjusted earnings of $0.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer says on track to deliver ~$4.5B in cost savings by end of 2025
EST Pfizer (PFE) says on track to deliver ~$4.5B in cost savings by end of 2025Maximize Your Portfolio with Data Driven Insights:Leverage ...
Crain's New York1d
Pfizer gets unexpected boost from Covid vaccine and pill
Sales of the Covid vaccine and pill were around $550 million more than analysts had been expecting for the quarter. Pfizer ...